

1. Explain the steps in the biosynthesis of androgens and their regulations.

❖ *Sites of synthesis:* Testes, ovaries, adrenal cortex, and placenta.


Testicular androgens are synthesized from cholesterol derived from:

- 1) Leydig cells in the testes, which synthesize cholesterol and store it as cholesterol ester.
- 2) Plasma by receptor-mediated uptake.

❖ **Rate-limiting step:** Cholesterol delivery to the inner mitochondrial membrane by the transport protein, steroidogenic acute regulatory protein (STAR).

❖ *Steps:*

- 1) Conversion of cholesterol to *pregnenolone* by mitochondrial enzyme complex cytochrome P450 side chain cleavage (P450_{sc}), which catalyzes oxidative side chain cleavage of cholesterol. This step is regulated by LH and ACTH.
- 2) Translocation of pregnenolone from Leydig cells to the endoplasmic reticulum where the remaining biosynthetic reactions occur.
- 3) Formation of testosterone from pregnenolone by the concerted action of the enzymes such as 3 β -hydroxysteroid dehydrogenase (3 β -O₂HSD), $\Delta^{5,4}$ isomerase, 17 α -hydroxylase, C₁₇₋₂₀ lyase, and 17 β -hydroxysteroid dehydrogenase (17 β -O₂HSD).
- 4) In addition to testosterone, small quantities of dehydroepiandrosterone, androstenediol, dihydrotestosterone (DHT), and 17 β -estradiol are also synthesized by the testes.
- 5) *Estradiol* is derived mostly from aromatization of testosterone in peripheral tissues in males
- 6) In females, testosterone is mostly derived from the adrenals, and only one-third is synthesized in the ovaries.



❖ Regulation:

- The anterior pituitary hormone LH regulates the synthesis and secretion of testosterone by the following sequence of events:
 - Binding to receptors on the plasma membrane of Leydig cells.

- Activation of adenylate cyclase
- Increase in cAMP levels.
- Increase in the rate of cholesterol side chain cleavage.
- **Regulation of LH secretion:**
 - By GnRH from the hypothalamus.
 - Feedback by testosterone that may be exerted at the level of the hypothalamus or the anterior pituitary.
- *The regulatory effect of ACTH on the adrenals is similar to that of LH.*
- **FSH**
 - Sensitizes Leydig cells to the actions of LH by increasing the number of LH receptors.
 - Promotes the synthesis of androgen-binding protein (ABP) by the Sertoli cells.
 - ABP binds testosterone and transports it from the Leydig cells to the site of spermatogenesis.
 - Secretion is inhibited by inhibin produced by the Sertoli cells.

2. How is testosterone transported?

About 97-99% of testosterone is transported in circulation bound to the following proteins:

- *Sex hormone-binding globulin (SHBG), or testosterone-estrogen-binding globulin (TEBG), a β -globulin synthesized in the liver, accounts for most of the testosterone binding. SHBG synthesis is increased by estrogens and decreased by androgens.*
- Plasma albumin.

The free fraction, which constitutes only 1-3% of total testosterone, is the biologically active hormone.


3. How is testosterone metabolically activated and inactivated?

Metabolic activation

- Less than 10% of testosterone is activated to *dihydrotestosterone (DHT)* or *estradiol*, and 90% is converted to excretory metabolites.
- Testosterone is converted to its metabolically active form dihydrotestosterone by the enzyme *5 α - reductase* in male accessory organs, brain, skin, and hair follicles. DHT is a potent androgen.
- Aromatization of testosterone forms estradiol in peripheral tissues such as adipose tissue.

Metabolic inactivation

- Metabolic inactivation of testosterone takes place in the liver.
- Testosterone is converted to the 17-ketosteroids, androsterone and etiocholanolone, which undergoes conjugation with glucuronate or sulphate to form water-soluble compounds that are excreted in the urine.

**4. Elucidate the biological actions of testosterone?**

Testosterone and DHT exert the following biological effects:

- *Sexual differentiation during embryonic development, and development of male secondary sexual characteristics.* Testosterone is necessary for sexual differentiation and spermatogenesis, whereas DHT is essential for development of the male external genitalia. Both testosterone and DHT are required for the male phenotype.
- *Anabolic and growth promoting effects* such as growth of bone, increase in skeletal muscle mass, and redistribution of fat.

Mechanism of action:

- Free testosterone enters the cytoplasm of target cells through the plasma membrane where it is converted to DHT.
- Both testosterone and DHT bind to a specific intracellular receptor and the hormone-receptor complex binds to nuclear chromatin selectively activating transcription of specific genes.
- Testosterone increases the activity of DNA polymerase and thymidine kinase, and the synthesis of androgen-binding protein.

5. Outline the causes and diagnostic tests for hypogonadism.

Hypogonadism refers to a clinical condition characterized by defective spermatogenesis and/or testosterone production.

❖ **Causes** : Hypogonadism may be classified into two types:

- **Primary hypogonadism** due to testicular disease with defective seminiferous tubular function, decreased spermatogenesis, and infertility, or defective Leydig cell function with failure of spermatogenesis.
 - ✓ *Klinefelter's syndrome* with 47 XXY genotype and enzyme defects such as 5 α -reductase.
 - ✓ Bilateral testicular torsion.
 - ✓ Radiation and cytotoxic drugs.
- **Secondary hypogonadism** may be due to:
 - ✓ Pituitary disorders panhypopituitarism, prolactinomas.
 - ✓ Hypothalamic disorders such as Kallman syndrome.

❖ **Diagnostic Tests**

- *Measurement of plasma testosterone*: Levels are low in both primary and secondary hypogonadism.
- *Measurement of LH and FSH*: Plasma LH is increased in Leydig cell failure, and plasma FSH in defective seminiferous tubular function. Decrease in both LH and FSH with oligospermia suggestive of pituitary or hypothalamic disease.
- *hCG stimulus test*: Administration of human chorionic gonadotropin (hCG) to test Leydig cell function.
 - ✓ Testosterone is estimated in blood drawn at 9.00 hours.
 - ✓ hCG 2000 IU is administered by intramuscular injection on day 1 and 3, and blood withdrawn on the fifth day for testosterone estimation.
 - ✓ An increase in plasma testosterone is seen in normal subjects, whereas in primary testicular failure, the response is decreased or absent
 - ✓ The response may, however, be normal in secondary testicular failure.
- GnRH test is used in the differential diagnosis of hypogonadism.
 - ✓ The test involves injection of GnRH (100 ug i.v.) and measurement of plasma LH and FSH before, and at 30 and 60 minutes after GnRH injection.
 - ✓ In pituitary disease, the response of LH and FSH to GnRH may be normal, decreased, or absent; whereas in hypothalamic disease, the response may be delayed, normal, or decreased.

6. Give a brief account of the biosynthesis of estrogen and its regulation.

- *Site of synthesis:* Ovary in non-pregnant females, the testes in males. Estrogen biosynthesis -also occurs in the liver, muscle, adipose tissue, hypothalamus, and hair follicles.
- *Precursor molecule:* Testosterone.
- *Conversion of testosterone to estradiol* is accomplished by a microsomal enzyme system called the aromatase complex in a process involving three successive hydroxylations and requiring three molecules each of NADPH and O₂.
- In males, peripheral aromatization of testosterone accounts for significant production of estrogens.
- *Adrenal androgens* are responsible for estrogen synthesis in postmenopausal women and for about 50% of estrogen synthesis during pregnancy.

Regulation

- LH stimulates theca cells to synthesize androgen precursors of estrogens.
- **FSH**
 - ✓ Stimulates growth of the ovarian follicle.
 - ✓ stimulates estrogen synthesis by granulosa cells.
 - ✓ Stimulates development of LH receptors on both theca and granulosa cells.
 - ✓ In inhibited by **inhibin**.
- Secretion of LH and FSH
 - ✓ Is regulated by GnRH.
 - ✓ Is inhibited by estrogen.

7. Discuss the causes, diagnosis, and management of amenorrhea.

Amenorrhea refers to the absence of menstruation.

❖ Causes:

- Non-endocrinal causes such as pregnancy and menopause.
- Endocrinal causes such as:
 - 1) *Primary ovarian failure* as in *Turner's syndrome* with 45X0 karyotype, characterized by developmental abnormalities, delayed puberty, low plasma estrogens, and increase in FSH and LH.
 - 2) *Polycystic ovary syndrome* (Stein-Leventhal syndrome), characterized by large polycystic ovaries, high plasma LH levels, chronic anovulation, obesity, androgen excess, hirsutism, and infertility.
 - 3) *Hypogonadotropic hypogonadism* resulting from pituitary or hypothalamic disease as in:

- ✓ Panhypopituitarism following treatment of pituitary adenomas by surgery or radiation.
- ✓ Prolactinomas.
- ✓ Kallman syndrome, due to defective GnRH synthesis or secretion, characterized by sexual1 immaturity and eunuchoid habitus.
- ✓ Deficiencies of GH, ACTH, thyroid hormone, and vasopressin.
- ✓ Excessive weight loss with anorexia nervosa.
- ✓ Malignancies.
- ✓ End-stage kidney disease.

❖ **Diagnosis**

- Increase in plasma FSH with decrease in estradiol suggests ovarian failure.
- Increase in plasma LH in the absence of pregnancy indicates polycystic ovary syndrome.
- Normal or low plasma FSH and LH levels with low plasma estradiol levels suggest pituitary or hypothalamic disorder.

❖ **Management**

- Bromocriptine administration in amenorrhea due to a pituitary tumor.
- Cyclical estrogen and progesterone replacement in patients with ovarian, pituitary, or hypothalamic disease, when fertility is not required.
- Administration of FSH and LH in pituitary failure if fertility is required.
- Administration of clomiphene in hypothalamic disease to block estrogen receptors in the hypothalamus, and to stimulate GnRH with secretion of LH and FSH.

8. **Outline the laboratory tests for the investigation of infertility.**

The laboratory tests for investigation of infertility include the following:

❖ **In females:**

- Plasma progesterone level is a reliable indicator of ovulation. A value of < 10 nmol/L indicates failure in ovulation or luteal function.
- Ovarian ultrasound examination to monitor follicular development and ovulation.
- Evaluation of luteal function by histological examination of an endometrial biopsy specimen.

❖ **In males:**

- Semen analysis.
- Evaluation of plasma FSH.
- Low plasma testosterone with increase in LH indicates Leydig cell failure.
- A decrease in both plasma LH and testosterone requires evaluation of pituitary and hypothalamic function.

- High plasma FSH indicates failure of seminiferous tubules, while low FSH with oligospermia pinpoints pituitary or hypothalamic disorder.
 - High plasma prolactin indicates pituitary tumor.
-

Good Luck

Prof. Dr. Tarik H. Al-Khayat

Printed By: Ali Al-Taie [AT]

Mohammed Al-Haddad

ممثل المرحلة : حسين شاكر محمد

.....

"Good advice is always certain to be ignored, but that's no reason not to give it."

Agatha Christie, British Novelist